CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Erlotinib +2 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00531960
NCT00531960Phase 2Completed
CompareCT.gov

A Randomized, Open-label Study Comparing the Anti-tumor Effect of Treatment With Tarceva Plus Avastin Versus Chemotherapy Plus Avastin in Patients With Advanced Non-small Cell Lung Cancer

Hoffmann-La Roche·interventional·Posted Sep 19, 2007·Updated Nov 11, 2014

In Brief

A Phase 2 clinical trial evaluating Erlotinib, Bevacizumab, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 124 participants across 57 sites in 13 countries.

Detailed Summary

This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer. Patients will be randomized to receive either Tarceva 150mg p.o. daily plus Avastin 15mg/kg i.v. every 3 weeks, or standard platinum-based chemotherapy (4-6 cycles) plus Avastin. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Belgium, France, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, South Korea, Spain, Taiwan, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2007
Enrollment StartJan 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.8 years ago

Interventions

Erlotinibdrug

150 mg, PO, daily

Bevacizumabdrug

15 mg/kg, IV, Day 1 of Cycles 1 through 7

Standard platinum-based chemotherapydrug

At the discretion of the investigator